Biotech Values

[jq1234]

GLPG: GSK2586184 met primary endpoint in Phase 2a psoriasis study

“Study JAK116679 was a phase 2a multi-centre, randomised, double-blind, placebo-controlled,
dose ranging study (100mg bid, 200mg bid, 400mg bid) that evaluated the safety and efficacy of GSK2586184 compared compared with placebo in 66 patients with chronic plaque psoriasis. Preliminary results showed that a significantly higher proportion of patients treated with GSK2586184 at the 400mg bid dose met the primary endpoint compared to placebo. The primary endpoint was defined as achieving =75% improvement from baseline in Psoriasis Area Severity Index (PASI75) score at Week 12. PASI75 for patients randomised to placebo was in the range expected.

During the treatment period the most common adverse events occurring with a frequency of more
than 20% on either placebo or pooled GSK2586184 were headache (36% placebo, 27% GSK2586184) and nasopharyngitis (21% placebo, 29% GSK2586184). A final analysis of the data from study JAK116679 will be submitted for presentation at an upcoming scientific congress and/or a peer-reviewed publication. GSK remains responsible for the study and intends to review the complete data from all GSK2586184 studies before determining next steps.”

http://www.glpg.com/files/4313/9771/4017/184_psoriasis_topline_FINAL.pdf